Fewer than 20% of U.S. adults eligible for lung cancer screening comply with USPSTF guideline

Phyllis Harris appointed chief legal and risk officer at ACS

Phyllis Harris was appointed chief legal and risk officer of American Cancer Society, effective June 23.

June 27, 2025

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

City of Hope has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health within the U.S. Department of Health and Human Services. The grant will help City of Hope create a biomap of tumor changes that cause immunotherapy resistance in advanced or metastatic non-small cell lung cancer.

June 20, 2025

Vol.51 No.24

Drugs & Targets

FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC

FDA has approved Ibtrozi (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

June 13, 2025

Vol.51 No.23

Clinical

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

For more than a year before her stage 4 lung cancer was found, 35-year-old Alisa Secaida, a never-smoker and a physically active Southern Californian, had been experiencing a persistent cough and, increasingly, fatigue.

June 06, 2025

Vol.51 No.22

By Claire Marie Porter

Obituary

Harmon Eyre, former ACS chief medical and scientific officer, dies at 84

Harmon Eyre, MD, died on May 31 in Salt Lake City. He was 84 years old. From 1993 to 2008, he served as the chief medical and scientific officer (CMSO) of the American Cancer Society.

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.

June 06, 2025

Vol.51 No.22

Fewer than 20% of U.S. adults eligible for lung cancer screening comply with USPSTF guideline

YOU MAY BE INTERESTED IN

Phyllis Harris appointed chief legal and risk officer at ACS

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

Harmon Eyre, former ACS chief medical and scientific officer, dies at 84

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

Renew today!

Subscriber content

Never miss an issue!

Login

Fewer than 20% of U.S. adults eligible for lung cancer screening comply with USPSTF guideline

YOU MAY BE INTERESTED IN

Phyllis Harris appointed chief legal and risk officer at ACS

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC

Young women are now diagnosed with cancer at twice the rate of young menThe face of cancer is changing at a time when research is plagued by existential threats

Harmon Eyre, former ACS chief medical and scientific officer, dies at 84

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

Never miss an issue!

Login

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats